-
Something wrong with this record ?
Re: Gemcitabine and Cisplatin plus Nivolumab as Organ-sparing Treatment for Muscle-invasive Bladder Cancer: A Phase 2 Trial. Galsky MD, Daneshmand S, Izadmehr S, et al. Nat Med 2023;29:2825-34
SF. Shariat, E. Laukhtina
Language English Country Switzerland
Document type Clinical Trial, Phase II, Journal Article
- MeSH
- Cisplatin therapeutic use MeSH
- Gemcitabine * MeSH
- Humans MeSH
- Urinary Bladder Neoplasms * drug therapy MeSH
- Neoadjuvant Therapy MeSH
- Nivolumab therapeutic use MeSH
- Antineoplastic Combined Chemotherapy Protocols therapeutic use MeSH
- Muscles MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial, Phase II MeSH
Department of Urology 2nd Faculty of Medicine Charles University Prague Czechia
Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria
Department of Urology University of Texas Southwestern Dallas TX USA
Department of Urology Weill Cornell Medical College New York NY USA
Hourani Center for Applied Scientific Research Al Ahliyya Amman University Amman Jordan
Institute for Urology and Reproductive Health Sechenov University Moscow Russia
Karl Landsteiner Institute of Urology and Andrology Vienna Austria
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24014166
- 003
- CZ-PrNML
- 005
- 20240905133354.0
- 007
- ta
- 008
- 240725s2024 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.eururo.2024.01.024 $2 doi
- 035 __
- $a (PubMed)38360442
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, University of Texas Southwestern, Dallas, TX, USA; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czechia; Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. Electronic address: shahrokh.shariat@meduniwien.ac.at
- 245 10
- $a Re: Gemcitabine and Cisplatin plus Nivolumab as Organ-sparing Treatment for Muscle-invasive Bladder Cancer: A Phase 2 Trial. Galsky MD, Daneshmand S, Izadmehr S, et al. Nat Med 2023;29:2825-34 / $c SF. Shariat, E. Laukhtina
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a gemcitabin $7 D000093542
- 650 _2
- $a cisplatina $x terapeutické užití $7 D002945
- 650 _2
- $a nivolumab $x terapeutické užití $7 D000077594
- 650 12
- $a nádory močového měchýře $x farmakoterapie $7 D001749
- 650 _2
- $a svaly $7 D009132
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
- 650 _2
- $a neoadjuvantní terapie $7 D020360
- 655 _2
- $a klinické zkoušky, fáze II $7 D017427
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Laukhtina, Ekaterina $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia
- 773 0_
- $w MED00001669 $t European urology $x 1873-7560 $g Roč. 85, č. 5 (2024), s. 501-502
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38360442 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240725 $b ABA008
- 991 __
- $a 20240905133348 $b ABA008
- 999 __
- $a ok $b bmc $g 2143761 $s 1226032
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 85 $c 5 $d 501-502 $e 20240215 $i 1873-7560 $m European urology $n Eur Urol $x MED00001669
- LZP __
- $a Pubmed-20240725
